Proton Therapy Publication Proton Therapy Publication
Menu

A multicenter high-quality data registry for advanced proton therapy approaches: the POWER registry.

March 2024
Executive summary

This article describes the POWER registry set up by the European Institute of Oncology (IEO), Milan, Italy. All patients with any type of oncologic disease (benign and malignant disease) eligible for proton therapy treated at IEO will be included in the registry, with a particular focus on the use of hypofractionation. 

Key content topics
Hypofractionation
Survival
Toxicity

Related contents

Webinar
March 29, 2023
Hypofractionation in Proton Therapy: radiobiological bases and clinical applications
Roberto
Orecchia
Barbara
Jereczek
Daniela
Alterio
Dante
Amelio
Jiri
Kubes
Link to the fully detailed content
Proton Therapy Publication
March 2023
A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose.
en
Link to the fully detailed content
Proton Therapy Publication
Proton therapy publication
November 2022
Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis.
Link to the fully detailed content
Proton Therapy Publication
April 2022
Outcome after Radiotherapy for Vestibular Schwannomas – Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy.
en
Link to the fully detailed content
Proton Therapy Publication
Proton therapy publication
December 2021
FLASH Radiotherapy Using Single-Energy Proton PBS Transmission Beams for Hypofractionation Liver Cancer: Dose and Dose Rate Quantification.
Link to the fully detailed content
Proton Therapy Publication
Proton therapy publication
November 2021
Clinical Effectiveness of Hypofractionated Proton Beam Therapy for Liver Metastasis From Breast Cancer.
Link to the fully detailed content
Proton Therapy Publication
Proton therapy publication
November 2021
Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy.
Link to the fully detailed content